Aardvark Therapeutics Statistics
Total Valuation
AARD has a market cap or net worth of $242.99 million. The enterprise value is $101.82 million.
Important Dates
The next confirmed earnings date is Wednesday, August 13, 2025, after market close.
Earnings Date | Aug 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
AARD has 21.70 million shares outstanding. The number of shares has increased by 170.95% in one year.
Current Share Class | 21.70M |
Shares Outstanding | 21.70M |
Shares Change (YoY) | +170.95% |
Shares Change (QoQ) | +64.98% |
Owned by Insiders (%) | 14.49% |
Owned by Institutions (%) | 17.94% |
Float | 11.18M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.61 |
P/TBV Ratio | 1.77 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.04, with a Debt / Equity ratio of 0.00.
Current Ratio | 14.04 |
Quick Ratio | 13.76 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.09% and return on invested capital (ROIC) is -22.98%.
Return on Equity (ROE) | -33.09% |
Return on Assets (ROA) | -21.76% |
Return on Invested Capital (ROIC) | -22.98% |
Return on Capital Employed (ROCE) | -29.79% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.67M |
Employee Count | 22 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Dividends & Yields
AARD does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -170.95% |
Shareholder Yield | -170.95% |
Earnings Yield | -15.08% |
FCF Yield | n/a |
Analyst Forecast
The average price target for AARD is $33.00, which is 194.64% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $33.00 |
Price Target Difference | 194.64% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |